TxCell SA, a biotechnology company, has announced positive immuno-monitoring results of the Phase I/II study in Crohn’s disease with Ovasave.
The open label, multicenter CATS1 study included 20 patients with severe chronic active Crohn’s disease, who had failed current treatments, including multiple biologics.
The Ovasave treatment impacted the immune system specifically in patients responding to Ovasave with a decrease in blood pro-inflammatory monocytes subpopulations and with an inhibition of the immune response to Ovasave-specific antigen.
The mechanism of action of Ovasave, composed of antigen-specific Treg cells, was supported by the correlation between patient’s clinical improvement and antigen-specific immuno-suppression.
TxCell chief scientific officer Arnaud Foussat said the antigen-specificity of the Treg cells in Ovasave represents an important component of their therapeutic potential.
